Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

08-06-2021 | ASCO 2021 | Conference coverage | Video

PEACE-1 points to benefit of adding abiraterone to ADT–docetaxel in de novo mCSPC

Karim Fizazi describes results from the phase 3 PEACE-1 trial suggesting that the combination of abiraterone, androgen deprivation therapy, and docetaxel could be an option for patients with a new diagnosis of metastatic castration-sensitive prostate cancer (5:58).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

25-04-2019 | Castration-sensitive prostate cancer | News

LATITUDE final analysis confirms abiraterone benefit for mCSPC

02-06-2019 | Castration-sensitive prostate cancer | Conference coverage | News

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

14-06-2019 | Castration-sensitive prostate cancer | Conference coverage | News

ENZAMET supports enzalutamide use in men with metastatic CSPC

09-02-2021 | Prostate cancer | News

Network meta-analysis identifies best ADT add-ons for mCSPC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits